

Research Article

Effect of *Allium stracheyi* on behavior of zebrafish: a pharmacological approach

Sanjay Kumar¹, Himanshu Joshi¹, Jeevan Chandra¹, Pankaj Bahuguna¹, Vivek Kumar Kedia², Rakesh Kumar³

¹Department of Zoology, LSM Govt. Post Graduate College, Pithoragarh, Uttarakhand, India

²Department of Botany, Govt. Post Graduate College, Talwari, Chamoli, Uttarakhand, India

³Department of Zoology, Pt. LMS, Govt. Post Graduate (Autonomous) College, Rishikesh, Dehradun, Uttarakhand, India

***Corresponding author**

Dr. Rakesh Kumar

Email: rkneuron@gmail.com

Abstract: Anxiety disorders are prevalent condition that affect emotion and cognitive behaviour and are associated with substantial impairments in both productive and social roles. Pharmacological intervention is the main therapeutic approach. Benzodiazepines are among most frequently prescribed anxiolytics. Several clinical problems are associated with the existing anxiolytics being prescribed and therefore herbal medicines are being considered as an alternative to the complementary medicine. In the present study methanolic extract of *Allium stracheyi* (Baker) was studied for its anxiolytic property in widely accepted zebrafish behavioural models of anxiety. The observations indicate that *Allium stracheyi* imparts mild anxiolytic activity.

Keywords: Anxiety, behaviour, *Allium stracheyi*, diazepam, zebrafish

INTRODUCTION

Behaviour is the most complex function of the nervous system. Adverse psychosocial factors, diseases, drugs, stress and environmental changes affect the neuronal system of an organism which leads to behavioural disturbances. Neurotransmitters play an important role in behaviour regulation. Any alteration or impairment in the neurotransmitter life cycle such as hypo/hyperactivity may change the behavioural responses leading to psychiatric illness [1-5]. Anxiety is an important component of psychiatric or medical condition [6] which ultimately decreases the quality of life. They are considered among the most prevalent psychiatric syndromes, affecting 10% to 30% of the general population of industrialized societies [7,8]. They affect emotion and cognition and exhibit > 50% co-morbidity with depression. Since anxiety and panic disorders are the common psychiatric disorders, one of the therapeutic approaches used is pharmacological intervention to solve these problems. Selectively acting drugs can be used to treat anxiety and other psychiatric disorders but the major disadvantage of the synthetic drugs is physical dependence or other side effects [9]. Previously alcohol, barbiturates and meprobamate were employed to alleviate anxiety. Anxiolytics and cognitive behavioural therapy have been in practice [10] but, many patients remain untreated, experience adverse effects of drugs [11], or do not get benefited [12]. Benzodiazepines are among the most frequently

prescribed anxiolytics and thus produce their effect by facilitating GABA neurotransmission within CNS [13]. Breier and Paul [14], suggested that benzodiazepines/GABA receptor complex is involved in the pathogenesis of anxiety and benzodiazepines are considered as drug of choice in the treatment of anxiety [15]. But now it is widely accepted that clinical problems associated with benzodiazepines are the fairly high risk of dependence, tolerance and addiction in long term use [16]. Abuse liability has also been documented among vulnerable groups [17]. Other side effects include adverse effects on behavior, cognition, immunity and occurrence of peptic ulcer or hypertension [18]. Furthermore, these drugs may have adverse effects on the fetus during pregnancy and on the neonate during lactation [19].

A number of herbal medicines are commonly used for the treatment of neurological and psychiatric disorders [20]. It has been estimated that 43% of anxiety sufferers use some form of complementary therapy [21]. The most popular treatments include herbal medicines [22] and anxiety disorders are amongst the most common reason for people to try herbal medicines [23].

Considerable interest has been generated by the possibility of identifying new drugs from plant source by using zebrafish (*Danio rerio*) as a suitable

animal model [24, 25]. Zebrafish model of anxiety and behavioral assays are currently used for high-throughput phenotyping and testing of various psychotropic drugs [26, 27, 28, 29]. Commonly used anxiolytics such as buspirone and diazepam are effective in zebrafish [30]. The reported behavioral responses to known anxiolytic or anxiogenic drugs indicates that zebrafish demonstrate high translation value in stress and anxiety-related pharmacological research.

Allium stracheyi (Baker) is a readily available perennial herb mainly found at the height of 2500-3000 meters of Alpine Himalayas of Uttarakhand, India [31]. Whole plant (flowers, leaves, root and bulb) is being used in traditional medicine by the local people for the treatment of various ailments including alleviation of inflammation and painful conditions [32], in the treatment of Jaundice, cold, cough, wound healing and other stomach problem [33, 34]. Nair and Nair, (1999) [35] reported various phytochemical constituents found in the plant material. Experimental studies indicate the use of *Allium stracheyi* as anti-inflammatory and analgesic activity, evaluated in carrageen induced rat paw edema method [36]. Anti-inflammatory, analgesic potential and relative toxicity of the plant extract has also been studied [37]. Since very few studies have been done, therefore, this plant was considered for pharmacological evaluation to find anxiolytic activity in zebrafish model of anxiety.

MATERIAL AND METHOD

Animals

Adult Zebrafish (*Danio rerio*) 3-5 cm in length were collected from Ben River, Pantnagar, Uttarakhand. The animals were maintained in the department animal unit in groups of 20-25, in 10-15 litre aquarium tanks for two months prior to the setup of the experiment. The animals were provided with a clean environment in a properly functioning aquarium under controlled condition of alkalinity, pH (6.8-7.5), temperature (26-28.5 °C), light condition 12:12 (light: dark) hardness (75–200 mg/L CaCO₃), ammonia, dissolve oxygen (7.8 mg/L at 28.0 °C), salinity (0.25–0.75 ppt) and conductivity was monitored on regular basis to ensure good water quality for housing zebrafish [38]. Animals were fed 1-2 times daily of fish food. All fishes were naive, and were allowed ten days to adapt the laboratory environment before experimentation.

Collection of plant material and preparation of standardized extract

Whole plants of *Allium stracheyi* (Baker) were collected from high altitude (Munshyari Tehsil) of district Pithoragarh, Uttarakhand and were identified from the Department of Botany, LSM Govt. Post Graduate College, Pithoragarh. Air dried whole plant of *Allium stracheyi* were used for methanolic extraction by

percolation. The residue obtained after removing solvent was dried in vacuum and macerated with acetone to give free flowing powder. The standard drug used in the study, benzodiazepine known anxiolytic (diazepam) was purchased from Ranbaxy, India.

Drug Administration

The drug was prepared immediately before use and administered through dissolving in water. Diazepam was used at the doses of 0.5, 1.0, 2.0 and 4.0 mg/litre and methanolic extract of *Allium stracheyi* as test drug was used at the dose of 50, 100, 200 and 400 mg/liter. Individual zebrafish was transferred from their home tank to a 250 ml beaker filled with 200 ml distilled water (control) or 200 ml distilled water treated with drug.

Experimental Procedure

Behavioural test were conducted between 10:00 AM to 3:00 PM. Before experimentation, zebrafish were transferred in their home cages from the animal unit to the experimental room one hour before each test session. After the habituation period in the laboratory the zebrafish were subjected to the test. In each study the zebrafish were randomly selected (n= 8) and divided into groups; Group-I placebo control and group-II standard drug (diazepam) treated and group-III test drug (*Allium stracheyi*). Each subject is randomly assigned to a treatment group. At one time one animal from particular group immersed in a solution containing the drug/vehicle for 30 min prior to behavioural observation. Experiments were conducted 30 minutes after vehicle/drug administration to the respective group. All the apparatus were cleaned thoroughly before and after each trial to remove any trace of odour. The experiments were done in a sound attenuated room and each six minute test sessions were recorded via an overhead video camera which is used to analyze behaviour later. After six minutes the zebrafish was removed from the test tank. A number of tests session were conducted to observe the behaviour of zebrafish. All behavioural recordings were carried out with an observer not aware of the treatment and behavioural endpoints of the zebrafish. The following tests (aquatic light and dark transition and open field test) were conducted to study the effect of *Allium stracheyi* on behaviour of zebrafish.

Aquatic light/dark transition test (Scototaxis)

Scototaxis is very similar to murine light/dark box [43], which exploits the tendency of zebrafish to explore a novel environment when confronted with the aversive properties of a brightly lit area (scotophilia, scototaxis) [43]. Analogous to rodent model, zebrafish exhibit a natural preference for the dark side when given a free choice between a dark and a light chamber [44, 45, 46]. This test has been used to investigate the anxiolytic or anxiogenic properties of a variety of drugs

[47]. Studies show that anxiolytic drugs increase the exploratory behaviour and time spent in white compartment while anxiogenic drugs cause the opposite effect [47, 48, 49].

Open field test

Open field exploration task is one of the popular tests of anxiety in rats [50]. This test is readily adaptable to zebrafish and therefore is widely used [40]. In rodents, a suppression of exploratory behaviour includes freezing, thigmotaxis and a reduction in locomotor activity are the behavioural measures of anxiety but in fish freezing and thigmotaxis have been considered as indicators of anxiety [28, 51]. In open field exploration task, zebrafish initially exhibit fear [28, 52] including thigmotaxis/centrophobic behaviour as observed in rodents.

RESULTS AND DISCUSSION

Behavioural studies on aquatic animal are gradually increasing exponentially. Several assays are being used specifically to test anxiety in the zebrafish. One stimulus that causes anxiety in zebrafish is novelty indicated by the presence of the fish at the bottom periphery (thigmotaxis) of the tank. Another index of anxiety in zebrafish is the preference for dark over light environments, or scototaxis. Anxious fish displays a

preference for dark surroundings and freeze when forced into light surroundings. Additionally, bottom-dwelling, leaping, hyperactivity and erratic movement have also indicators of anxiety in the 'open tank' paradigm.

The effect of *Allium stracheyi* was studied at the dose of 50, 100, 200 and 400 mg/litre and compared with control and standard drug diazepam (0.5, 1.0, 2.0, 4.0 mg/l) in open field and light and dark transition test. At all doses *Allium stracheyi* did not produce significant effects in all the behavioural paradigms of open field and light and dark transition test (Table-1 & 2). *Allium stracheyi* produced enhanced time spent by each subject in the center of the tank but which is mild and not significant while time spent by the fish in periphery was significant compared with control and diazepam. Time spent on freezing in the center, number of transition between zones and time spent on freezing in periphery were also not affected markedly compared to control. In the light and dark transition test, time spent by each subject in the white half of the tank was not significant enhanced at all doses whereas mild alterations were observed in the number of entries and time spent in the black half of the tank and number of entries to the white half of the tank compared to control animals.

Table-1: Light and Dark Transition test:

Drug/Dose n=8	Time spent in the black half of the apparatus (Seconds)	Number of entries to the black half of the apparatus	Time spent in the white half of the apparatus (seconds)	Number of entries to the blackwhite half of the apparatus
Control	241.375±5.560	12.125±3.173	101.875±3.739	4.5±1.467
Diazepam 0.5 mg/L	228.375±3.956	12.75±1.864	124.25±2.288	9.625±1.165
Diazepam 1.0 mg/L	181.125±7.383	9.375±1.463	143±3.932	8.125±1.359
Diazepam 2.0 mg/L	155.5±2.341	11.375±1.874	199.875±3.993	14.5±2.027
Diazepam 4.0 mg/L	179.375±3.538	7.25±1.231	180.625±3.538	9.5±1.928
<i>Allium stracheyi</i> 50 mg/L	218.875±4.955	13.5±1.928	92±5.508	6.75±1.149
<i>Allium stracheyi</i> 100 mg/L	201.125±5.354	11.375±2.380	110.5±5.836	8.625±0.983
<i>Allium stracheyi</i> 200 mg/L	209.25±8.611	12.375±1.246	102.25±5.040	12.625±1.463
<i>Allium stracheyi</i> 400 mg/L	198.375±8.567	13.125±1.847	139.25±3.448	6.125±1.359

Values represent the group mean± SEM, (n=8), P<0.05 vs. control

Table-2: Open Field Test:

Drug/Dose n=8	Time spent in the centre of the tank (seconds)	Time spent in the periphery of the tank (seconds)	Number of transition between zones	Time spent on freezing in the center (seconds)	Time spent on freezing in periphery (seconds)
Control	66.25±4.049	242.125±5.725	13.75±1.756	16.375±1.394	33.75±1.149
Diazepam 0.5 mg/L	245.25±7.800	76.125±2.596	2±0.766	11.75±0.733	22.625±1.766
Diazepam 1.0 mg/L	309.125±4.184	28.625±4.265	6.875±0.820	6.5±0.766	13.375±1.528
Diazepam 2.0 mg/L	282±4.847	39.875±4.876	4.875±0.690	11.875±1.122	24.75±2.245
Diazepam 4.0 mg/L	246.125±5.427	54.625±1.975	1.375±0.428	29±3.221	27.875±1.429
<i>Allium stracheyi</i> 50 mg/L	97.875±4.795	219±3.455	12.375±1.528	15.75±1.231	27.125±2.275
<i>Allium stracheyi</i> 100 mg/L	87.875±5.092	237.875±4.434	11.25±1.756	13.125±1.950	22.5±1.399
<i>Allium stracheyi</i> 200 mg/L	98.875±2.778	217±4.335	9.625±1.651	12.5±1.824	29.125±1.285
<i>Allium stracheyi</i> 400 mg/L	92.125±6.311	218.75±5.286	12.75±1.864	14.375±1.766	33.625±2.119

Values represent the group mean± SEM, (n=8), P<0.05 vs. control

Anxiety has been postulated to be involved in the etiopathogenesis of psychosomatic disorders including psychiatric disorders [18]. The failure of successful adaptation during stressful situations results in anxiety disorders [53]. Prolonged stressful conditions have been associated with dysfunction of several neurotransmitters [54] resulting in behavioral changes as well as a cascade of hormonal release from the hypothalamus–pituitary–adrenal (HPA) axis leading to disorders like anxiety and depression [55, 56]. No biological cause has been identified for anxiety disorders [57]. Heisler et al (1998) [58] suggested 5HT subtype, 5HT_{1A} has been the main serotonin receptor implicated in fear and anxiety and 5HT_{1A} receptor partial or total agonist showed anxiolytic properties. According to McEwen (2000) [59] HPA axis dysregulation caused by stress results in excess production of noradrenalin and corticosterone, sensitizes peripheral inflammatory response [60], and increases anxiety [61].

Since, anxiety is associated with behavioral responses that are replicable in animal models and altered by anxiolytic drugs. In anxiety model of fish, certain predation threat (predator odors, alarm pheromones or fleeing conspecifics) are typically used for anxiogenic effects [26]. Several assays were used to test antianxiety activity of *Allium stracheyi* in the present study and also used by others [40, 45]. In light and dark transition test; when anxious, fish displays a preference for dark surroundings and they freeze when forced into light surroundings [66] which was observed

in the study and these anxiogenic behaviour were mildly reverted by *Allium stracheyi* compared to control while benzodiazepines (diazepam) know anxiolytic significantly enhanced the the time spent in light area of the tank. In open field test [50], in which suppression of exploratory behaviour including freezing and thigmotaxis have been considered as indicator of anxiety (28, 51). *Allium stracheyi* at all doses produce mild decrease in the time spent in the periphery (thigmotaxis) of the tank, number of transition between zones, freezing in the center and periphery of the tank compared to control and diazepam. Additionally, bottom-dwelling (or diving), leaping, hyperactivity, and erratic movement have also been suggested as species-specific indicators of anxiety in the ‘open tank’ paradigm [27, 67]. The novel tank test is an alternative to open field test and commonly used to assess zebrafish behaviour and anxiety paradigms [39, 40, 41, 42]. This test exploits the natural tendency of zebrafish to seek refuge when exposed to a novel environment [27]. The mild anxiolytic effects of *Allium stracheyi* may have some other type of activity. Mechanism of action of anxiolytic plants may have interaction with some of the natural endogenous mediators in the body as reported by several scientific communities [62, 63]. It is evident that there could be a linkage in the interaction of serotonergic pathways and plant extract [64, 65]. 5HT subtype, 5HT_{1A} has been considered the main serotonin receptor implicated in fear and anxiety and 5HT_{1A} receptor partial or total agonist showed anxiolytic properties [58]. Breier and Paul [14], indicated that benzodiazepines/ γ -aminobutyric acid (BZ/GABA)

receptor complex is involved in the pathogenesis of anxiety and benzodiazepines produce their effects by facilitating GABA neurotransmission [13].

A recent study has shown that both basic and complex brain phenomena as well as endocrine mechanisms, share a substantial homology between zebrafish and mammals such as mice and men [68]. Zebrafish nervous system and brain aminergic systems share many structural properties with the mammalian systems (including humans) [69]. Since zebrafish possess all the classical vertebrate neurotransmitters, and their neuroendocrine system yields robust cortisol responses to stress, thus zebrafish model enable greater insight into neural mechanisms associated with anxiety-related disorders. Therefore zebrafish were used in the present study which serves as inexpensive and high-throughput models for the development of anxiolytic drugs. Benzodiazepine GABA-A receptors have been found in a wide variety of species including bony fishes [70] and have similar binding characteristics as those in rodents and humans [71-74]. Zebrafish have similar types of muscarinic and acetylcholine neurotransmitter receptors to the mammals. Studies have examined anxiety in zebrafish using anxiolytic agents such as nicotine [27], α -fluoromethylhistidine 75, ethanol [76] and diazepam [28]. Drug-evoked anxiety has also been reported in zebrafish using the benzodiazepine inverse agonist FG-7142 or following abrupt cessation of chronic cocaine administration [28].

Zebrafish brain aminergic system has many structural properties common to the mammalian systems. The noradrenergic, serotonergic, aminergic and histaminergic systems of zebrafish are highly similar to the mammalian system [77-79]. The basic and complex brain phenomena as well as endocrine mechanisms of zebrafish and mammals are substantially homologous [68]. Just like humans, zebrafish employs cortisol as the primary stress response hormone unlike corticosterone by rodents [80]. The hypothalamus pituitary inter renal (HPI) axis of zebrafish is homologous to the hypothalamus pituitary adrenal (HPA) axis of humans. Cortisol is the primary stress hormone in both species [81]. Zebrafish model enables greater insight into neural mechanism associated with anxiety related disorders since it possess all the classical vertebrates' neurotransmitters and its neuroendocrine system yields robust cortisol responses to stress. There are several characteristics which make zebrafish an important test subject which could prove useful in a greater understanding of neuropharmacological mechanisms in mammals and facilitate behaviour based drug discovery [24]. Zebrafish have robust physiological responses and quantifiable behavioural and neuropathological phenotypes analogous to humans [82]. It also offers an alternative and efficient mode of drug delivery via the gills [27, 51, 10]. Beneficial

property like low maintenance cost and rapid life cycle make easy to maintain a large number of zebrafish in a relatively small area which is important for large scale behavioural studies and psychopharmacological screening of medicinal plants for drug development [24, 40].

Overall observation indicates when a zebrafish was presented to an unfamiliar environment it showed robust anxiety-like behavioural responses, which were measured in open field test and light/dark transition. Methanolic extract of *Allium stracheyi* reverted anxiety-like behavioural responses in zebrafish but not significantly compared to control and diazepam. This indicates that crude extract of *Allium stracheyi* imparted mild anxiolytic property. Further studies are needed to isolate and characterize the active component of *Allium stracheyi* to evaluate their antianxiety effect in various behavioural test models.

REFERENCES

1. De Angelis L; Experimental anxiety and antidepressant drugs: the effects of moclobemide, a selective reversible MAO-A inhibitor, fluoxetine and imipramine in mice. *Naunyn Schmiedeberg Arch. Pharmacol*, 1996; 354 (3): 379-383.
2. Clement Y, Calatayud F; Genetic basis of anxiety-like behaviour: a critical review. *Brain Res Bull*, 2002; 57 (1): 57-71.
3. Conti L, Jirout M; Identification of quantitative trait loci for anxiety and locomotion phenotypes in rat recombinant inbred strains. *Behav Genet*, 2004; 34.
4. Ditzen C, Jastorff A; Protein biomarkers in a mouse model of extremes in trait anxiety. *Mol. Cell Proteomics*, 2006; 5(10): 1914-1920.
5. Kalueff AV, Wheaton M; what's wrong with my mouse model? Advances and strategies in animal modelling of anxiety and depression. *Behav Brain Res*, 2007; 179 (1): 1-18.
6. Lavie CJ, Milani RV; Prevalence of anxiety in coronary patients with improvement following cardiac rehabilitation and exercise training. *Am J Cardiol*, 2004; 93: 336-339.
7. Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JRT, et al. The economic burden of anxiety disorders in the 1990s. *J Clin Psychiatry* 1999; 60: 427-35.
8. Wittchen HU, Hoyer J. Generalized anxiety disorder: nature and course. *J Clin Psychiatry* 2001; 62:15-21.
9. Bloom FE; Neurotransmission and central Nervous System. *In: Goodman and Gilman's Pharmacological Basis of Therapeutics* (eds) Joel G. Hardman, Lee E Limbird, Perry B. Molinoff, Raymond W. Ruddon, Alfred Goodman Gilman. McGraw-Hill, New York, 9th ed. 1996; 267-293.

10. Gerlai, R., Lee, V., Blaser, R., 2006. Effects of acute and chronic ethanol exposure on the behavior of adult zebrafish (*Danio rerio*). *Pharmacol Biochem Behav.* 85(4), 752-61.
11. Woods JH, Katz JL, Winger G; Abuse liability of benzodiazepines. *Pharmacol Rev*, 1987; 39: 251–419.
12. Issakidis C, Andrews G; Service utilisation for anxiety in an Australian community sample. *Soc. Psychiatry Psychiatry Epidemiol*, 2002; 37: 153–163.
13. Eldefrawai AT, Eldefrawai ME; Receptor for gamma amino-butyric acid and voltage dependent chloride channels as target for drugs and toxins. *FASEB L*, 1987; 1:262-271.
14. Breier A, Paul SM; The GABA/BZs receptor: implication for the molecular basis of anxiety. *J Psychiatric Res*, 1990; 24: 91-104.
15. Hollister LE, Muller-Oerlinghausen B, Rickds K, Shader RI; Clinical use of benzodiazepines. *Clin Psychopharmacology*, 1993; 13 suppl 1: 1S-169S.
16. Foltin RW, Evans SM; Performance effect of drugs of abuse;a methodological survey. *Hum Psychopharmacology* 1993; 8: 9-19.
17. Sellar EM, Ciraulo DA, DuPont RL, Griffiths RR, Kosten TR, Romach MK, Woody GE; Alprazolam and benzodiazepine dependence. *J Clin Psychiat*, 1993; 54: 64-75, 1993.
18. Elliott GR, Eisdorfer C; Stress and human health. New York: Springer Publishing; 1982.
19. Trevor AJ, Way WL; Sedative–hypnotic drugs. In: Katzung BG, editor. *Basic and clinical pharmacology*. New York: Lange Medical; 2001.p. 364– 81.
20. Beaubrun G, Gray GE; A review of herbal medicines for psychiatric disorders. *Psychiatr Serv* 2000; 51:1130-4.
21. Eisenberg DM, David RB, Ettner SL; Trends in alternative medicine use in the United States. *J Am Med Assoc*, 1998; 280: 1569–1575.
22. Astin JA; Why patients use alternative medicine: results of a national study. *J Am Med Assoc*, 1998; 279: 1548–1553.
23. Wong AHC, Smith M, Boon HS; Herbal medicines in psychiatric practice. *Psychiatry*, 1998; 55: 1033–1044.
24. Kokel D, Peterson RT; "Chemobehavioural phenomics and behaviour-based psychiatric drug discovery in the zebrafish." *Brief Funct Genomic Proteomic*, 2008; 7(6): 483-90.
25. Guo S; "Linking genes to brain, behavior and neurological diseases: what can we learn from zebrafish?" *Genes Brain Behav*, 2004; 3(2): 63-74.
26. Blaser RE, Gerlai R; Behavioral phenotyping in zebrafish: comparison of three behavioural quantification methods. *Behav Res Methods*, 2006; 38: 456–69.
27. Levin ED, Bencan Z, Cerutti DT; Anxiolytic effects of nicotine in zebrafish. *Physiol Behav*, 2007; 90(1):54–58.
28. Lopez-Patino MA, Yu L, Cabral H, Zhdanova IV; Anxiogenic effects of cocaine withdrawal in zebrafish. *Physiol Behav*, 2008; 93(1–2):160–71.
29. Zachary Bencan, Damiyon Sledge, Edward D. Levin. Buspirone, chlordiazepoxide and diazepam effects in a zebrafish model of anxiety *Pharmacology, Biochemistry and Behavior*, 2009; 94: 75–8.
30. Bencan Z, Sledge D, Levin ED; Buspirone, chlordiazepoxide and diazepam effects in a zebrafish model of anxiety. *Pharmacol Biochem Behav*, 2009; 94: 75–80.
31. Mann A, Bansa A, Clifford LC; An antifungal property of crude plant extracts from *Anogeissus leiocarpus* and *Terminalia avicennioides*. *Tanzania J Health Res*, 2008; 10: (1) 34-38.
32. Farooquee A, Nehal BS, Majila, Kala BS; Indigenous Knowledge Systems and Sustainable Management of Natural Resources in a High Altitude Society in Kumaun Himalaya, *Indian Journal of Human Ecology*, 2004; 16(1): 33-42.
33. Kumari P, Singh BK, Joshi GC, Tewari LM, Veterinary Ethnomedicinal Plants in Uttarakhand Himalayan Region, India, *Ethnobotanical Leaflets*, 2009; 13: 1312-1327.
34. Samal PK, Dhyani PP, Bollo M; Medicinal Plant Resources in Nanda Devi Biosphere Reserve in the Central Himalayas, *Indian Journal of Traditional Knowledge*, 2010; 9: 140-144.
35. Nair NV, Nair S; Analysis of genetic diversity and phylogeny in *Saccharum* and related genera using RAPD markers. *Genet Res Crop Evol*, 1999; 46: 73–79.
36. Winter CA, Risely EA, Nuss GV; Carrageenin induced Edema in Hind Paw of Rat as an Assay for Anti-inflammatory Drugs. *Proceeding of Society for Experimental Biology and Medicine*, 1962; 111: 544-547.
37. Shashi Ranjan, Vikash S Jadon, Nitish Sharma, Kamini Singh, Varsha Parcha, Sanjay Gupta, Bhatt JP; Anti-inflammatory and Analgesic Potential of Leaf Extract of *Allium Stracheyi*. *Journal of Applied Sciences Research*, 2010; 6(2): 139-143.
38. Christian Lawrence; The husbandry of zebrafish (*Danio rerio*): A review. *Aquaculture*, 2007; 269: 1-20.
39. Stewart A, Wong K, Cachat J, Gaikwad S, Kyzar E, Wu N, Hart P, Piet V, Utterback E, Elegante M, Tien D, Kalueff A; Zebrafish models to study drug abuse related phenotypes *Rev Neurosci*, 2010b; 22: 95-105.
40. Egan RJ, Bergner CL; Understanding behavioral and physiological phenotypes of stress and anxiety in zebrafish. *Behav Brain Res*, 2009; 205 (1): 38-44.

41. Cachat JM, Stewart A; Deconstructing adult zebrafish behaviour with swim trace visualizations. In *Zebrafish Neurobehavioral Protocols*. (Eds. Kalueff, A.V. and Cachat, J.) (Humana Press, New York), 2010c.
42. Wong K, Elegante M; Analyzing habituation responses to novelty in zebrafish (*Danio rerio*). *Behav Brain Res*, 2010b; 208(2): 450-457.
43. Bourin M, Hascoet M; The mouse light/dark box test. *European Journal of Pharmacology*, 2003; 463: 55-65.
44. Serra EL, Medalha CC, Mattioli R; Natural preference of zebrafish (*Danio rerio*) for a dark environment. *Braz J Med Biol Res*, 1999; 32: 1551-1553.
45. Maximino C, Marques de Brito T, Dias CA, Gouveia A Jr, Morato S; Scototaxis as anxiety-like behaviour in fish. *Nat Protoc*, 2010; 5: 209-216.
46. Champagne DL, Hoefnagels CC; Translating rodent behavioural repertoire to zebrafish (*Danio rerio*): relevance for stress research. *Behav Brain Res*, 2010; 214 (2): 332-342.
47. Sackerman J, Donegan JJ, Cunningham CS, Nguyen NN, Lawless K, Long A, Benno, RH, Gould GG; Zebrafish behavior in novel environments: effects of acute exposure to anxiolytic compounds and choice of *Danio rerio* line. *Integr J Comp Psychol*, 2010; 23: 43-61.
48. Grossman L, Utterback U, Stewart A, Gaikwad S, Wong K, Elegante M, Tan J, Gilder T, Wu N, DiLeo J, Cachat J, Kalueff AV; Characterization of behavioural and endocrine effects of LSD on zebrafish. *Behav Brain Res*, 2010; 214: 277-284.
49. Stewart A, Kadri F, DiLeo J, Chung K, Cachat J, Goodspeed J, Suci C, Roy S, Gaikwad S, Wong K, Elegante M, Elkhayat S, Wu N, Gilder T, Tien D, Kalueff AV; The developing utility of zebrafish in modeling neurobehavioural disorders. *Int J Comp Psychol*, 2010; 23: 104-121.
50. Prut L, Belzung C; The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. *Eur J Pharmacol*, 2003; 463: 3-33.
51. Lockwood B, Bjerke S, Kobayashi K, Guo S; Acute effects of alcohol on larval zebrafish: A genetic system for large-scale screening. *Pharmacology Biochemistry and Behaviour*, 2004; 77: 647-654.
52. Aihart MJ, Lee DH, Wilson TD, Miller BE, Miller MN, Skalko RG; Movement disorders and neurochemical changes in zebrafish larvae after bath exposure to fluoxetine (PROZAC). *Neurotoxicol Teratol*, 2007; 29: 652-64.
53. Chrousos GP, Gold PW; The concept of stress and stress system disorders. *JAMA*, 1992; 267:1244-52.
54. Gonzalo A, Carrasco LD, Van DK; Neuroendocrine pharmacology of stress. *European Journal of Pharmacology*, 2003; 463: 235-272.
55. Jayanthi LD, Ramamoorthy S; Regulation of monoamine transporters: influence of psychostimulants and therapeutic antidepressants. *American Association of Pharmaceutical Scientists Journal*, 2005; 27: 728-738.
56. Filip M, Frankowska M, Zaniewska M, Golda A, Przegalinski E; The serotonergic system and its role in cocaine addiction. *Pharmacological Reports*, 200; 557: 685-700.
57. Parra KV, Adrian Jr JC, Gerlai R. The synthetic substance hypoxanthine 3-N-oxide elicits alarm reactions in zebrafish (*Danio rerio*). *Behav Brain Res* 2009; 205: 336-41.
58. Heisler LK et al; Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. *Proc Natl Acad Sci*, 1998; 95:15049-15054.
59. McEwen BS; The neurobiology of stress: from serendipity to clinical relevance. *Brain Res*, 2000; 886: 172-189.
60. Neigh GN, Gasper ER, Bilbo SD, Traystman RJ, DeVries AC; Cardiac arrest/cardiopulmonary resuscitation augment cell-mediated immune function and transiently suppress humoral immune function. *J Cereb Blood Flow Metab*, 2005; 25: 1424-1432.
61. Neigh GN, Kofler J, Meyers JL, Bergdall V, La Perle KM, Traystman RJ, DeVries AC; Cardiac arrest/cardiopulmonary resuscitation increases anxiety-like behavior and decreases social interaction. *J Cereb Blood Flow Metab*, 2004b; 24: 372-382.
62. Contarino A, Dellu F, Koob GF, Smith GW, Lee K, Vale W, Gold LH; Reduced anxiety like and cognitive performance in mice lacking the corticotropin-releasing factor receptor. *Brain Res*, 1999; 835: 9.
63. Shih JC, Ridd MJ, Chen K, Meehan WP, Kung M, Self I, Demaeyer E, Ketanserin and tetrabenzine abolish aggression in mice lacking mono amine oxidase A, *Brain Res*, 1999; 835: 112.
64. Sanchez C, Arnt J, Hyttel J, Moltzen ZK; The role of serotonergic mechanisms in inhibition of isolation-induced aggression in rats and mice. *Psychopharmacol*, 1993; 110: 59.
65. Kadaba BKA; A Safe herbal treatment for anxiety. *Brit J Phytother*, 1994; 3: 1500.
66. Blaser, RE, Chadwick L, McGinnis GC; Behavioural measures of anxiety in zebrafish (*Danio rerio*). *Behav Brain Res*, 2010; 208: 56-62.
67. Blaser RE, Gerlai R; Behavioural phenotyping in zebrafish: comparison of three behavioural quantification methods. *Behav Res Methods*, 2006; 38: 56-69.

68. Miklosi A, Andrew RJ; "The zebrafish as a model for behavioral studies. *Zebrafish*, 2006; 3(2): 227-34.
69. Guo S; "Linking genes to brain, behavior and neurological diseases: what can we learn from zebrafish?" *Genes Brain Behav*, 2004; 3(2): 63-74.
70. Nielsen M, Braestrup C, Squires RF. Evidence for a late evolutionary appearance of brain specific benzodiazepine receptors: an investigation of 18 vertebrate and 5 invertebrate species. *Brain Res* 1978; 141:342-6.
71. Carr RL, Couch TA, Liu J, Coats JR, Chambers JE. The interaction of chlorinated alicyclic insecticides with brain GABA (A) receptors in channel catfish (*Ictalurus punctatus*). *J Toxicol Environ Health Part A* 1999; 56:543-53.
72. Anzelius M, Ekstrom P, Mohler H, Richards JG; Immunocytochemical localization of GABA-A receptor beta 2/beta 3-subunits in the brain of Atlantic salmon (*Salmo salar* L). *J Chem Neuroanat*, 1995a; 8:207-21.
73. Anzelius M, Ekstrom P, Mohler H, Richards JG; Immunocytochemical localization of the GABA-A/benzodiazepine receptor beta2/beta3 subunits in the optic tectum of the salmon. *J Recept Signal Transduct Res* 1995b; 15: 413-25.
74. Wilkinson M, Wilkinson DA, Khan I, Crim LW; Benzodiazepine receptors in fish brain: [3H] flunitrazepam binding and modulatory effects of GABA in rainbow trout. *Brain Res Bull* 1983; 10: 301-3.
75. Pietsaro N, Kaslin J, Anichtchik OV, Panula P. Modulation of the histaminergic system and behaviour by alpha-fluoromethylhistidine in zebrafish. *J Neurochem* 2003; 86: 432-41.
76. Gerlai R, Lee V, Blaser R; Effects of acute and chronic ethanol exposure on the behavior of adult zebrafish (*Danio rerio*). *Pharmacol Biochem Behav*, 2006; 85(4):752-61.
77. Tomasiewicz HG, Flaherty DB, Soria JP, Wood JG; Transgenic zebrafish model of neurodegeneration. *J Neuroscience Res*, 2002; 70(6): 734-45.
78. Panula P, Sallinen V, Sundvik M, Kolehmainen J, Torkko V, Tiitula A, Modulatory neurotransmitter systems and behavior: towards zebrafish models of neurodegenerative diseases. *Zebrafish*, 2006; 3: 235-47.
79. Bai Q, Mullett SJ, Garver JA, Hinkle DA, Burton EA; Zebrafish is evolutionarily conserved and expressed in dopaminergic neurons. *Brain Res*, 2006; 1113: 33-44.
80. Barcellos LJG, Ritter F, Kreutz LC, Quevedo RM, Bolognesi, daSilva L. Bedin, AC; Whole-body cortisol increases after direct and visual contact with a predator in zebrafish (*Danio rerio*) *Aquaculture*, 2007; 272: 774-8.
81. Alsop D, Vijayan MM; The zebrafish stress axis: molecular fallout from the teleost-specific genome duplication event, *Gen Comp Endocrinol*, 2009; 161: 62-66.
82. Moretz JA, Martins EP, Robison BD; Behavioral syndromes and the evolution of correlated behavior in zebrafish. *Behav Ecol*, 2007; 18: 556-562.